Novo Annual Review 2016
25 / 71
portfolio company achievements in 2016 btg ?
the acquisition of galil medical, a leading provider of cryoablation products used in the treatment of kidney and other cancers. ? launched the ßeta? radiation safety programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (sirt) with 90y microspheres. chr hansen ? launched a new coagulant, chy-max ® special ? a true game changer for soft cheese manufacturers and the food service sector. ? acquired lgg ® business from valio oy to further strengthen its microbial platform. ? acquired nutritional physiology company and expanded its business in probiotics to the livestock industry. eresearch technology ?
the acquisition of uk-based exco intouch, a leading provider of patient engagement and digital health solutions for clinical trials. ? integrated the market-leading fractional exhaled nitric oxide (feno) measurement device by aerocrine ? a circassia-owned subsidiary ? into ert?s diagnostic platform for e.g. spirometry and ecg home monitoring of clinical trials endpoints. inogen ? released innovative inogen one g4? oxygen concentrator. the ultra-portable device is the smallest and lightest oxygen concentrator that the company has ever produced. orexo ? and mundipharma
the submission of a regulatory marketing authorisation application (maa) for zubsolv (buprenorphine and naloxone) sublingual tablet to the european medicines agency (ema), seeking approval for the treatment of opioid dependence. sonion ? and invensense
the release of the o-series mems microphone in two very small form factors, thereby completing a critically important development programme. symphogen ? and baxalta
a broad strategic immune- oncology collaboration. symphogen
usd 175 million upfront, in addition to potential future milestone payments and royalties. synlab ?
a successful re-financing of its debt by issuing a eur 940 million senior secured floating rate notes at par. ?
integration of the merger process between labco and synlab. veloxis pharmaceuticals ?
that once-daily envarsus xr ® (tacrolimus extended-release tablets)
us food and drug administration (fda) approval for label enhancements. these enhancements are related to pharmacokinetics. xellia pharmaceuticals ? reached agreement with us food and drug administration (fda) on modifications for the newly-acquired cleveland site, and subsequently
approval for its use as a packaging facility ? expanded croatian anti-infective product and innovation capabilities to tackle antimicrobial resistance crisis. 25 large investments